Abstract
Background Pancreatic cancer is a serious threat to human health. Enhanced CT is widely used in the diagnosis of pancreatic cancer. However, false-positive results on enhanced CT can lead to misdiagnosis and incorrect surgery or treatment, while false-negative results on enhanced CT can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive and false-negative rates of enhanced CT in pancreatic tumors. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in pancreatic cancer.
Patients and methods 62 subjects (malignant group, n=37; benign group, n=25) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.
Results The sensitivity of YiDiXie™ SS was 100% (95% CI: 90.6% - 100%) and its specificity was 68.0% (95% CI: 48.4% - 82.8%). This means that YiDiXie™ SS has extremely high sensitivity and high specificity in pancreatic tumors.YiDiXie™-HS has a sensitivity of 94.6% (95% CI: 82.3% - 99.0%) and a specificity of 84.0% (95% CI: 65.3% - 93.6%). This means that YiDiXie™-HS has high sensitivity and specificity in pancreatic tumors.YiDiXie™-D has a sensitivity of 73.0% (95% CI: 57.0% - 84.6%) and its specificity is 92.0% (95% CI: 75.0% - 98.6%). This means that YiDiXie™-D has high sensitivity and very high specificity in pancreatic tumors.YiDiXie™ SS had a sensitivity of 100% (95% CI: 88.6% - 100%) and a specificity of 66.7% (95% CI: 30.0% - 94.1%) in patients with positive enhanced CT. This means that the application of YiDiXie™ SS reduces the false-positive rate of enhanced CT by 66.7% (95% CI: 30.0% - 94.1%) with essentially no increase in malignancy leakage. YiDiXie™-HS had a sensitivity of 85.7% (95% CI: 48.7% - 99.3%) and a specificity of 84.2% (95% CI: 62.4% - 92.5%) in enhanced CT-negative patients. This means that YiDiXie™-HS reduces the false-negative enhancement CT rate by 84.2% (95% CI: 62.4% - 92.5%). YiDiXie™-D has a sensitivity of 73.3%(95% CI: 55.6% - 85.8%) and a specificity of 83.3%(95% CI: 43.6% - 99.1%) in patients with positive enhancement CT. This means that YiDiXie™-D reduces the false positive rate of enhanced CT by 83.3%(95% CI: 43.6% - 99.1%). YiDiXie™-D had a sensitivity of 71.4% (95% CI: 35.9% - 94.9%) and a specificity of 94.7% (95% CI: 75.4% - 99.7%) in patients with negative enhanced CT. This means that YiDiXie™-D reduces the false-negative rate of enhanced CT by 71.4% (95% CI: 35.9% - 94.9%) while maintaining high specificity.
Conclusion YiDiXie ™ -SS has very high sensitivity and high specificity in pancreatic tumors.YiDiXie ™ -HS has high sensitivity and high specificity in pancreatic tumors.YiDiXie™-D has high sensitivity and very high specificity in pancreatic tumors.YiDiXie™ SS significantly reduces pancreatic-enhanced CT with essentially no increase in delayed treatment of malignant tumors. The YiDiXie™-HS significantly reduces the false negative rate of pancreatic enhanced CT. the YiDiXie™ -D significantly reduces the false positive rate of pancreatic enhanced CT or significantly reduces the false negative rate of pancreatic enhanced CT while maintaining a high level of specificity. the YiDiXie™ test is of great diagnostic value in pancreatic cancer, and it is expected to solve the problem of “ too high a false positive rate” and “ too high a false negative rate” of pancreatic enhanced CT.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results were updated. Tabel 2-8 were reviesed.
Data Availability
All data produced in the present study are contained in the manuscript.
